Author:
Bakker Wilfried A. M.,Thomassen Yvonne E.,van ’t Oever Aart G.,Westdijk Janny,van Oijen Monique G.C.T.,Kersten Gideon F.A.,van der Pol Leo A.,Hertroys Rudy,van den Heuvel Nico,Hendriks Jan
Reference8 articles.
1. Aylward, R.B., Sutter, R.W., Cochi S.L., Thompson K.M., Jafari H., Heymann D. (2006). Risk management in a polio-free world. Risk Analysis 26, 1441–1448
2. Bakker, W.A.M., Thomassen, Y.E., Van der Pol, L.A. (2010). Scale-down approach for animal-free polio vaccine production. In: Noll, T. (ed.) Cells & Culture, Proc. 20th ESACT Meeting. Vol. 4(6). (pp. 541–550) Dresden, Germany
3. Heymann, D.L., Sutter R.W., Aylward R.B. (2005). A global call for new polio vaccines. Nature 434 (7034), 699–700
4. Kersten, G., Hazendonk, T., Beuvery, C. (1999). Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17, 2059–2066
5. Kreeftenberg, H., Van der Velden, T., Kersten, G., Van der Heuvel, N., De Bruijn, M. (2006). Technology transfer of Sabin-IPV to new developing country markets. Biologicals 34, 155–158